Alison Broomall
About Alison Broomall
Alison Broomall is the Associate Director of Customer & Portfolio Value Generation at Bristol Myers Squibb, specializing in patient engagement and value creation within the healthcare sector.
Title
Alison Broomall holds the position of Associate Director, Customer & Portfolio Value Generation at Bristol Myers Squibb. She is based in Summit, New Jersey, United States.
Professional Experience at Bristol Myers Squibb
Currently, Alison Broomall is the Associate Director, Customer & Portfolio Value Generation at Bristol Myers Squibb. In this role, she focuses on creating value for customers and managing the portfolio in a strategic manner. Her responsibilities involve navigating the complexities of the healthcare landscape to support patient-centric strategies and providing guidance on regulatory matters related to patient-focused drug development (PFDD).
Previous Roles in the Healthcare Sector
Before joining Bristol Myers Squibb, Alison Broomall held various significant roles in the healthcare sector. She was a Patient Engagement Consultant at The Stem in Red Bank, NJ, and a Patient Innovation & Engagement Strategist at Astellas Pharma US in Greater NYC. Additionally, she served as Practice Lead, Customer Engagement, Life Sciences SME at Slalom Consulting and Director, Commercial Excellence at HighPoint Solutions. She has a wealth of experience in patient engagement strategies and life sciences.
Educational Background
Alison Broomall studied at the Massachusetts Institute of Technology - Sloan School of Management, focusing on 'Artificial Intelligence: Implications for Business Strategy.' She earned a B.A. in Politics with honors from the University of California, Santa Cruz, and an M.A. in Foreign Policy from American University.
Specialization in Patient Engagement and Strategy
Alison Broomall specializes in developing patient engagement frameworks that help organizations incorporate the patient perspective in value creation. Her work involves promoting patient-centric strategies, infusing flexibility and scalability into these strategies, and ensuring compliance with the evolving regulatory landscape around patient-focused drug development (PFDD). She excels in identifying actionable intersections between patient desires and organizational capabilities.